Min Li, Lujie Liu, Yurong Kang, Shanlong Huang, Yanfeng Xiao
Introduction: Thrombospondin 1 (THBS1) is a highly expressed adipokine in adults with obesity. In the present study, we aimed to investigate the clinical significance of THBS1in children with obesity and nonalcoholic fatty liver disease (NAFLD) and determine the effect of metformin on THBS1 expression in dietary-induced obese (DIO) mice.
Methods: A cross-sectional study was conducted among 78 obese children and 35 nonobese children. Anthropometric parameters, clinical data, and circulating THBS1 levels were measured. The expression of THBS1 was detected in the serum and liver tissue from diet-induced obese mice (C57BL/6) with or without metformin treatment.
Results: Higher THBS1 levels were observed in children with NAFLD and higher SDS-BMI. Individuals in the higher THBS1 quartile had a higher prevalence of hypo-high-density lipoprotein cholesterol (HDL-C). Logistic regression analysis showed a significant correlation between THBS1 and NAFLD, as well as between hip circumference and leptin levels. Receiver-operating characteristic (ROC) analysis revealed that THBS1 was a more sensitive predictor of NAFLD than leptin. Additionally, metformin ameliorated hepatic steatosis and decreased hepatic THBS1 expression in high-fat diet (HFD)-fed mice.
Conclusions: Circulating THBS1 level may be a risk factor for NAFLD in obese children. Our findings provided a novel approach of metformin administration for the prevention and treatment of NAFLD. This study also confirmed that metformin decreased the expression of hepatic THBS in DIO mice.
{"title":"Circulating THBS1: A Risk Factor for Nonalcoholic Fatty Liver Disease in Obese Children.","authors":"Min Li, Lujie Liu, Yurong Kang, Shanlong Huang, Yanfeng Xiao","doi":"10.1159/000527780","DOIUrl":"https://doi.org/10.1159/000527780","url":null,"abstract":"<p><strong>Introduction: </strong>Thrombospondin 1 (THBS1) is a highly expressed adipokine in adults with obesity. In the present study, we aimed to investigate the clinical significance of THBS1in children with obesity and nonalcoholic fatty liver disease (NAFLD) and determine the effect of metformin on THBS1 expression in dietary-induced obese (DIO) mice.</p><p><strong>Methods: </strong>A cross-sectional study was conducted among 78 obese children and 35 nonobese children. Anthropometric parameters, clinical data, and circulating THBS1 levels were measured. The expression of THBS1 was detected in the serum and liver tissue from diet-induced obese mice (C57BL/6) with or without metformin treatment.</p><p><strong>Results: </strong>Higher THBS1 levels were observed in children with NAFLD and higher SDS-BMI. Individuals in the higher THBS1 quartile had a higher prevalence of hypo-high-density lipoprotein cholesterol (HDL-C). Logistic regression analysis showed a significant correlation between THBS1 and NAFLD, as well as between hip circumference and leptin levels. Receiver-operating characteristic (ROC) analysis revealed that THBS1 was a more sensitive predictor of NAFLD than leptin. Additionally, metformin ameliorated hepatic steatosis and decreased hepatic THBS1 expression in high-fat diet (HFD)-fed mice.</p><p><strong>Conclusions: </strong>Circulating THBS1 level may be a risk factor for NAFLD in obese children. Our findings provided a novel approach of metformin administration for the prevention and treatment of NAFLD. This study also confirmed that metformin decreased the expression of hepatic THBS in DIO mice.</p>","PeriodicalId":8269,"journal":{"name":"Annals of Nutrition and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9305319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Expression of Concern.","authors":"","doi":"10.1159/000529287","DOIUrl":"https://doi.org/10.1159/000529287","url":null,"abstract":"","PeriodicalId":8269,"journal":{"name":"Annals of Nutrition and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10400815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01Epub Date: 2022-10-06DOI: 10.1159/000526958
The following document is dedicated to compiling the abstracts of the communications and lectures of the FINUT 2022 Conference. The document comprises 111 abstracts of the guest speakers participating in the scientific symposia and special lectures and more than 230 abstracts for oral and poster communications, representing more than 20 countries. FINUT Conferences seek to open a place for contrasted science shared by the Ibero-American region, a necessary space to open opportunities and to display the research work done in Food and Nutrition. The main objective of the FINUT 2022 Conference is to create a space for the exchange and discussion of ideas related to the main challenges of Food and Nutrition in Iberoamerica, in order to offer solutions aimed at improving the health status of populations, taking into account the impact of social inequalities in the region. The scientific program of the Conference includes 40 parallel symposia, 5 breakfasts with the experts, and 11 special lectures. In this second edition the Conference focused on 4 topics: • Healthy Nutrition in the Life Cycle and Clinical Nutrition • Nutritional Epidemiology and Public Health Challenges in Iberoamerica • Safe, Healthy, Sustainable, and Social Food • Methods and Tools in Nutrition The entity organizing the Conference is the Ibero-American Nutrition Foundation (FINUT) which was established in 2011. FINUT is a non-profit and financially self-supporting entity; our vision is to promote research and training, identify problems of public interest and provide scientific answers; and involve all stakeholders in our cause. We work throughout the year in many scientific virtual activities with a large number of beneficiaries and the FINUT Conferences give us the opportunity to meet them personally. We wish to thank the Organizing, Scientific, and Local Committees for the enthusiasm and commitment dedicated to this conference, our sponsors for trusting us again, and take the opportunity we offer them to contact the most valuable part of our event, the delegates; professionals, academics, clinicians, researchers, and students in the areas of Food, Nutrition, and Health, to whom we also extend our most sincere gratitude. ¡See you at FINUT 2024!
{"title":"FINUT 2022 Conference Abstracts; October 9-11, 2022.","authors":"","doi":"10.1159/000526958","DOIUrl":"10.1159/000526958","url":null,"abstract":"<p><p>The following document is dedicated to compiling the abstracts of the communications and lectures of the FINUT 2022 Conference. The document comprises 111 abstracts of the guest speakers participating in the scientific symposia and special lectures and more than 230 abstracts for oral and poster communications, representing more than 20 countries. FINUT Conferences seek to open a place for contrasted science shared by the Ibero-American region, a necessary space to open opportunities and to display the research work done in Food and Nutrition. The main objective of the FINUT 2022 Conference is to create a space for the exchange and discussion of ideas related to the main challenges of Food and Nutrition in Iberoamerica, in order to offer solutions aimed at improving the health status of populations, taking into account the impact of social inequalities in the region. The scientific program of the Conference includes 40 parallel symposia, 5 breakfasts with the experts, and 11 special lectures. In this second edition the Conference focused on 4 topics: • Healthy Nutrition in the Life Cycle and Clinical Nutrition • Nutritional Epidemiology and Public Health Challenges in Iberoamerica • Safe, Healthy, Sustainable, and Social Food • Methods and Tools in Nutrition The entity organizing the Conference is the Ibero-American Nutrition Foundation (FINUT) which was established in 2011. FINUT is a non-profit and financially self-supporting entity; our vision is to promote research and training, identify problems of public interest and provide scientific answers; and involve all stakeholders in our cause. We work throughout the year in many scientific virtual activities with a large number of beneficiaries and the FINUT Conferences give us the opportunity to meet them personally. We wish to thank the Organizing, Scientific, and Local Committees for the enthusiasm and commitment dedicated to this conference, our sponsors for trusting us again, and take the opportunity we offer them to contact the most valuable part of our event, the delegates; professionals, academics, clinicians, researchers, and students in the areas of Food, Nutrition, and Health, to whom we also extend our most sincere gratitude. ¡See you at FINUT 2024!</p>","PeriodicalId":8269,"journal":{"name":"Annals of Nutrition and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Quantitative measurements of liver fat contents (LFCs) by magnetic resonance imaging derived-proton density fat fraction (MRI-PDFF) are accurate but limited by availability, convenience, and expense in the surveillance of metabolic associated fatty liver (MAFLD). Insulin resistance (IR) and steatosis-associated serum indices are useful in screening for MAFLD, but their value in monitoring MAFLD with or without chronic hepatitis B virus (CHB) infection remains unclear and we aimed to evaluate these scores in predicting changes in LFC.
Methods: We conducted a prospective study between January 2015 and December 2021 with 620 consecutive participants with MAFLD (212 participants with CHB) who received a 24-week lifestyle intervention. The homeostasis model assessment of IR (HOMA-IR), HOMA2 index, glucose-insulin ratio, quantitative insulin sensitivity check index, fasting insulin resistance index, fatty liver index (FLI), hepatic steatosis index (HSI), liver fat score (LFS), visceral adiposity index, and triglycerides * glucose were calculated.
Results: When using endpoints such as LFS improvements of ≥5% or 10% or escalations of ≥5%, LFS had the highest area under the curve (AUC) values at all endpoints for MAFLD alone (0.756, 95% CI: 0.707-0.805; 0.761, 95% CI: 0.705-0.818; 0.807, 95% CI: 0.713-0.901, all p < 0.05, respectively). With CHB, the FLI (AUC = 0.750) and HIS (AUC = 0.770) exhibited the highest AUCs between the former two outcomes, respectively, but no score could predict LFC escalation of ≥5%.
Conclusion: Among IR and steatosis scores, changes in LFC through lifestyle interventions can be captured with LFS possessing moderate precision but not in those with CHB.
{"title":"Comparisons of Insulin Resistance- and Steatosis-Based Scores in Monitoring Metabolic Associated Fatty Liver Disease Treatment Response.","authors":"Junzhao Ye, Yansong Lin, Congxian Shao, Yanhong Sun, Shiting Feng, Bihui Zhong","doi":"10.1159/000530531","DOIUrl":"10.1159/000530531","url":null,"abstract":"<p><strong>Background: </strong>Quantitative measurements of liver fat contents (LFCs) by magnetic resonance imaging derived-proton density fat fraction (MRI-PDFF) are accurate but limited by availability, convenience, and expense in the surveillance of metabolic associated fatty liver (MAFLD). Insulin resistance (IR) and steatosis-associated serum indices are useful in screening for MAFLD, but their value in monitoring MAFLD with or without chronic hepatitis B virus (CHB) infection remains unclear and we aimed to evaluate these scores in predicting changes in LFC.</p><p><strong>Methods: </strong>We conducted a prospective study between January 2015 and December 2021 with 620 consecutive participants with MAFLD (212 participants with CHB) who received a 24-week lifestyle intervention. The homeostasis model assessment of IR (HOMA-IR), HOMA2 index, glucose-insulin ratio, quantitative insulin sensitivity check index, fasting insulin resistance index, fatty liver index (FLI), hepatic steatosis index (HSI), liver fat score (LFS), visceral adiposity index, and triglycerides * glucose were calculated.</p><p><strong>Results: </strong>When using endpoints such as LFS improvements of ≥5% or 10% or escalations of ≥5%, LFS had the highest area under the curve (AUC) values at all endpoints for MAFLD alone (0.756, 95% CI: 0.707-0.805; 0.761, 95% CI: 0.705-0.818; 0.807, 95% CI: 0.713-0.901, all p < 0.05, respectively). With CHB, the FLI (AUC = 0.750) and HIS (AUC = 0.770) exhibited the highest AUCs between the former two outcomes, respectively, but no score could predict LFC escalation of ≥5%.</p><p><strong>Conclusion: </strong>Among IR and steatosis scores, changes in LFC through lifestyle interventions can be captured with LFS possessing moderate precision but not in those with CHB.</p>","PeriodicalId":8269,"journal":{"name":"Annals of Nutrition and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10534698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Expression of Concern.","authors":"","doi":"10.1159/000529290","DOIUrl":"https://doi.org/10.1159/000529290","url":null,"abstract":"","PeriodicalId":8269,"journal":{"name":"Annals of Nutrition and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10419211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01Epub Date: 2023-01-23DOI: 10.1159/000529217
Berthold Koletzko, Mary Fewtrell, Adamos Hadjipanayis
None (editorial).
{"title":"Promoting Breastfeeding and Interaction of Paediatric Associations with Commercial Providers of Nutritional Products: Are They Compatible?","authors":"Berthold Koletzko, Mary Fewtrell, Adamos Hadjipanayis","doi":"10.1159/000529217","DOIUrl":"10.1159/000529217","url":null,"abstract":"None (editorial).","PeriodicalId":8269,"journal":{"name":"Annals of Nutrition and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10258658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01Epub Date: 2023-08-22DOI: 10.1159/000533239
{"title":"Erratum.","authors":"","doi":"10.1159/000533239","DOIUrl":"10.1159/000533239","url":null,"abstract":"","PeriodicalId":8269,"journal":{"name":"Annals of Nutrition and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10050858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The nitrogen balance estimates a protein net difference. However, since it has a number of limitations, it is important to consider the trajectory of the nitrogen balance in the clinical course of critically ill patients.
Objectives: We herein exploratively classified the nitrogen balance trajectory using a machine learning method.
Method: This is a post hoc analysis of a single-center prospective study for the patients admitted to our Emergency and Critical Center ICU. The nitrogen balance was evaluated with 24-h urine collection from ICU days 1-10 with 9 points. K-means clustering was performed to classify the nitrogen balance trajectory. We also evaluated factors associated with uncovered clusters.
Results: Seventy-six eligible patients were included in the present study. After clustering, the nitrogen balance trajectory was classified into 4 classes. Class 1 was trajected as a negative balance over 10 days (24 patients). Class 2 had a positive conversion on day 3 or 4 (8 patients). Class 3 had a positive conversion on day 8 or 9 (28 patients). Class 4 initially had a positive balance and then converted to a negative balance (16 patients). Sepsis complication and steroid use were associated with negative nitrogen balance trajectory. Class 2 was associated with lower length of hospital stay and femoral muscle volume loss, however, frequently had frailty and sarcopenia on admission. Active nutrition therapy intention was not correlated with positive trajectory.
Conclusions: The nitrogen balance trajectory in critically ill patients may be classified into 4 classes for clinical practice. Among patients emergently admitted to the ICU, the positive conversion of the nitrogen balance might be delayed over 10 days.
{"title":"Explorative Clustering of the Nitrogen Balance Trajectory in Critically Ill Patients: A Preliminary post hoc Analysis of a Single-Center Prospective Observational Study.","authors":"Kensuke Nakamura, Kentaro Ogura, Hidehiko Nakano, Daisuke Ikechi, Masaki Mochizuki, Yuji Takahashi, Tadahiro Goto","doi":"10.1159/000532126","DOIUrl":"10.1159/000532126","url":null,"abstract":"<p><strong>Background: </strong>The nitrogen balance estimates a protein net difference. However, since it has a number of limitations, it is important to consider the trajectory of the nitrogen balance in the clinical course of critically ill patients.</p><p><strong>Objectives: </strong>We herein exploratively classified the nitrogen balance trajectory using a machine learning method.</p><p><strong>Method: </strong>This is a post hoc analysis of a single-center prospective study for the patients admitted to our Emergency and Critical Center ICU. The nitrogen balance was evaluated with 24-h urine collection from ICU days 1-10 with 9 points. K-means clustering was performed to classify the nitrogen balance trajectory. We also evaluated factors associated with uncovered clusters.</p><p><strong>Results: </strong>Seventy-six eligible patients were included in the present study. After clustering, the nitrogen balance trajectory was classified into 4 classes. Class 1 was trajected as a negative balance over 10 days (24 patients). Class 2 had a positive conversion on day 3 or 4 (8 patients). Class 3 had a positive conversion on day 8 or 9 (28 patients). Class 4 initially had a positive balance and then converted to a negative balance (16 patients). Sepsis complication and steroid use were associated with negative nitrogen balance trajectory. Class 2 was associated with lower length of hospital stay and femoral muscle volume loss, however, frequently had frailty and sarcopenia on admission. Active nutrition therapy intention was not correlated with positive trajectory.</p><p><strong>Conclusions: </strong>The nitrogen balance trajectory in critically ill patients may be classified into 4 classes for clinical practice. Among patients emergently admitted to the ICU, the positive conversion of the nitrogen balance might be delayed over 10 days.</p>","PeriodicalId":8269,"journal":{"name":"Annals of Nutrition and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10711758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41181889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01Epub Date: 2023-11-09DOI: 10.1159/000535007
Konstantinos Gkikas, Vaios Svolos, Richard Hansen, Richard K Russell, Konstantinos Gerasimidis
Background: A significant body of literature has interrogated the critical role of diet in the development and management of inflammatory bowel disease (IBD).
Summary: This review provides a summary and critical appraisal of the literature in this area, focussing on four distinct themes: nutritional epidemiology, animal and in vitro experiments, enteral nutrition, and food-based dietary therapies.
Key messages: Nutritional epidemiology and data from experiments in animals indicate that a western-type diet pattern is associated with increased risk of IBD onset. However, these findings have not been consistently replicated in the dietary management of IBD. Exclusive enteral nutrition (EEN) is the only dietary therapy with reproducible evidence of efficacy in the management of active Crohn's disease (CD). Use of EEN may also be useful for improving perioperative outcomes in CD, and as an adjuvant therapy to biologic therapy. Several dietary therapies for CD and ulcerative colitis have been proposed in the literature, but replication in well-controlled studies is needed before their routine use enters the clinical setting. Precision nutritional therapy might be an attractive therapeutic paradigm in a heterogenous disease like IBD. However, no recommendations for personalised dietary therapy can currently be made, and it is imperative we unravel the complex interplay between diet and gut inflammation before we are able to do so. Undoubtedly, diet is of critical importance in the development and management of IBD. However, the exact mechanism by which diet causes gut inflammation is still elusive, and dietary guidance is difficult to formulate.
{"title":"Take-Home Messages from 20 Years of Progress in Dietary Therapy of Inflammatory Bowel Disease.","authors":"Konstantinos Gkikas, Vaios Svolos, Richard Hansen, Richard K Russell, Konstantinos Gerasimidis","doi":"10.1159/000535007","DOIUrl":"10.1159/000535007","url":null,"abstract":"<p><strong>Background: </strong>A significant body of literature has interrogated the critical role of diet in the development and management of inflammatory bowel disease (IBD).</p><p><strong>Summary: </strong>This review provides a summary and critical appraisal of the literature in this area, focussing on four distinct themes: nutritional epidemiology, animal and in vitro experiments, enteral nutrition, and food-based dietary therapies.</p><p><strong>Key messages: </strong>Nutritional epidemiology and data from experiments in animals indicate that a western-type diet pattern is associated with increased risk of IBD onset. However, these findings have not been consistently replicated in the dietary management of IBD. Exclusive enteral nutrition (EEN) is the only dietary therapy with reproducible evidence of efficacy in the management of active Crohn's disease (CD). Use of EEN may also be useful for improving perioperative outcomes in CD, and as an adjuvant therapy to biologic therapy. Several dietary therapies for CD and ulcerative colitis have been proposed in the literature, but replication in well-controlled studies is needed before their routine use enters the clinical setting. Precision nutritional therapy might be an attractive therapeutic paradigm in a heterogenous disease like IBD. However, no recommendations for personalised dietary therapy can currently be made, and it is imperative we unravel the complex interplay between diet and gut inflammation before we are able to do so. Undoubtedly, diet is of critical importance in the development and management of IBD. However, the exact mechanism by which diet causes gut inflammation is still elusive, and dietary guidance is difficult to formulate.</p>","PeriodicalId":8269,"journal":{"name":"Annals of Nutrition and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72013301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01Epub Date: 2023-10-26DOI: 10.1159/000534725
Rasmus Stenlid, Sara Y Cerenius, Hannes Manell, Banu Küçükemre Aydin, Katharina Mörwald, Julian Gomahr, Marina Höghammar Mitkas, Ida Eriksson, Iris Ciba, Sabine Geiersberger, David Thivel, Daniel Weghuber, Peter Bergsten, Anders Forslund
Introduction: Obesity is associated with chronic inflammation. Chronic inflammation has also been linked to insulin resistance and type 2 diabetes, metabolic associated fatty liver disease, and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor analogs (GLP-1RA) are clinically used to treat obesity, with known anti-inflammatory properties. How the GLP-1RA exenatide effects inflammation in adolescents with obesity is not fully investigated.
Methods: Forty-four patients were randomized to receive weekly subcutaneous injections with either 2 mg exenatide or placebo for 6 months. Plasma samples were collected at baseline and at the end of the study, and 92 inflammatory proteins were measured.
Results: Following treatment with exenatide, 15 out of the 92 proteins were decreased, and one was increased. However, after adjustment for multiple testing, only IL-18Rα was significantly lowered following treatment.
Conclusions: Weekly injections with 2 mg of exenatide lowers circulating IL-18Rα in adolescents with obesity, which may be a potential link between exenatide and its anti-inflammatory effect in vivo. This contributes to exenatide's pharmaceutical potential as a treatment for obesity beyond weight control and glucose tolerance, and should be further studied mechanistically.
{"title":"Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial.","authors":"Rasmus Stenlid, Sara Y Cerenius, Hannes Manell, Banu Küçükemre Aydin, Katharina Mörwald, Julian Gomahr, Marina Höghammar Mitkas, Ida Eriksson, Iris Ciba, Sabine Geiersberger, David Thivel, Daniel Weghuber, Peter Bergsten, Anders Forslund","doi":"10.1159/000534725","DOIUrl":"10.1159/000534725","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity is associated with chronic inflammation. Chronic inflammation has also been linked to insulin resistance and type 2 diabetes, metabolic associated fatty liver disease, and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor analogs (GLP-1RA) are clinically used to treat obesity, with known anti-inflammatory properties. How the GLP-1RA exenatide effects inflammation in adolescents with obesity is not fully investigated.</p><p><strong>Methods: </strong>Forty-four patients were randomized to receive weekly subcutaneous injections with either 2 mg exenatide or placebo for 6 months. Plasma samples were collected at baseline and at the end of the study, and 92 inflammatory proteins were measured.</p><p><strong>Results: </strong>Following treatment with exenatide, 15 out of the 92 proteins were decreased, and one was increased. However, after adjustment for multiple testing, only IL-18Rα was significantly lowered following treatment.</p><p><strong>Conclusions: </strong>Weekly injections with 2 mg of exenatide lowers circulating IL-18Rα in adolescents with obesity, which may be a potential link between exenatide and its anti-inflammatory effect in vivo. This contributes to exenatide's pharmaceutical potential as a treatment for obesity beyond weight control and glucose tolerance, and should be further studied mechanistically.</p>","PeriodicalId":8269,"journal":{"name":"Annals of Nutrition and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}